US010660939B2

(12) **United States Patent**
**Spana et al.**

(10) **Patent No.: US 10,660,939 B2**
(45) **Date of Patent: May 26, 2020**

(54) **THERAPIES FOR OBESITY, DIABETES AND RELATED INDICATIONS**

(71) Applicant: **Palatin Technologies, Inc.**, Cranbury, NJ (US)

(72) Inventors: **Carl Spana**, West Harrison, NY (US); **John H. Dodd**, Spring Mills, PA (US); **Marie Makhlina**, Highland Park, NJ (US)

(73) Assignee: **Palatin Technologies, Inc.**, Cranbury, NJ (US)

( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 117 days.

(21) Appl. No.: **15/723,755**

(22) Filed: **Oct. 3, 2017**

(65) **Prior Publication Data**

US 2018/0153965 A1 Jun. 7, 2018

**Related U.S. Application Data**

(63) Continuation of application No. PCT/US2016/027402, filed on Apr. 14, 2016.

(60) Provisional application No. 62/147,256, filed on Apr. 14, 2015.

(51) **Int. Cl.**

| | |
|---|---|
| ***A61K 38/26*** | (2006.01) |
| ***A61K 38/12*** | (2006.01) |
| ***A61K 9/00*** | (2006.01) |
| ***A61P 3/00*** | (2006.01) |
| ***A61P 3/04*** | (2006.01) |
| ***A61P 3/10*** | (2006.01) |

(52) **U.S. Cl.**

CPC ..... ***A61K 38/26*** (2013.01); ***A61K 9/0019*** (2013.01); ***A61K 38/12*** (2013.01); ***A61P 3/00*** (2018.01); ***A61P 3/04*** (2018.01); ***A61P 3/10*** (2018.01)

(58) **Field of Classification Search**

CPC ..... A61K 38/26; A61K 38/12

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

| | | | |
|---|---|---|---|
| 4,938,763 | A | 7/1990 | Dunn et al. |
| 5,576,290 | A | 11/1996 | Hadley |
| 5,674,839 | A | 10/1997 | Hruby et al. |
| 6,432,438 | B1 | 8/2002 | Shukla |
| 6,579,968 | B1 | 6/2003 | Blood et al. |
| 6,673,767 | B1 | 1/2004 | Brodbeck et al. |
| 6,794,489 | B2 | 9/2004 | Blood et al. |
| 7,326,707 | B2 | 2/2008 | Sharma et al. |
| 7,354,923 | B2 | 4/2008 | Sharma et al. |
| 7,456,184 | B2 | 11/2008 | Sharma et al. |
| 7,662,771 | B2 | 2/2010 | Herr et al. |
| 7,834,017 | B2 | 11/2010 | Burris et al. |
| 7,947,841 | B2 | 5/2011 | Jungheim et al. |
| 7,964,601 | B2 | 6/2011 | Sharma et al. |
| 7,968,548 | B2 | 6/2011 | Sharma et al. |
| 8,298,561 | B2 | 10/2012 | Alessi et al. |
| 8,455,617 | B2 | 6/2013 | Dodd et al. |
| 8,455,618 | B2 | 6/2013 | Dodd et al. |
| 8,487,073 | B2 | 7/2013 | Shi et al. |
| 8,492,517 | B2 | 7/2013 | Yang et al. |
| 8,729,224 | B2 | 5/2014 | Shi et al. |
| 8,846,601 | B2 | 9/2014 | Shi et al. |
| 8,877,890 | B2 | 11/2014 | Yang et al. |
| 8,912,226 | B2 | 12/2014 | Grosch et al. |
| 8,933,194 | B2 | 1/2015 | Yang et al. |
| 9,089,538 | B2 | 7/2015 | Neerup et al. |
| 9,156,901 | B2 | 10/2015 | Riber |
| 9,186,392 | B2 | 11/2015 | Klein |
| 9,205,081 | B2 | 12/2015 | Toledano |
| 9,278,123 | B2 | 3/2016 | Sauerberg et al. |
| 2003/0032791 | A1 | 2/2003 | Robertson et al. |
| 2009/0142338 | A1 | 6/2009 | Levetan et al. |
| 2009/0156474 | A1 | 6/2009 | Roth et al. |
| 2011/0256130 | A1 | 10/2011 | Schultz et al. |
| 2012/0077957 | A1 | 3/2012 | Chen et al. |
| 2012/0178670 | A1 | 7/2012 | Riber |
| 2013/0030417 | A1 | 1/2013 | Alessi et al. |
| 2013/0090278 | A1 | 4/2013 | Alessi et al. |
| 2013/0157929 | A1 | 6/2013 | Riber et al. |
| 2013/0157935 | A1 | 6/2013 | Meier et al. |
| 2013/0157953 | A1 | 6/2013 | Petersen et al. |
| 2013/0316005 | A1 | 11/2013 | Pelaez et al. |
| 2013/0316941 | A1 | 11/2013 | Hamprecht et al. |
| 2014/0031287 | A1 | 1/2014 | Herr et al. |
| 2014/0080757 | A1 | 3/2014 | Tolborg |
| 2014/0128402 | A1 | 5/2014 | Pareek et al. |
| 2014/0336107 | A1 | 11/2014 | Tolborg et al. |
| 2014/0357575 | A1* | 12/2014 | Shi ..... C07K 5/1024 514/21.1 |

(Continued)

FOREIGN PATENT DOCUMENTS

| | | | |
|---|---|---|---|
| EP | 1 792 626 | A1 | 6/2007 |
| EP | 2 127 676 | A2 | 12/2009 |

(Continued)

OTHER PUBLICATIONS

Clemmensen et al., EMBO Mol. Med. 7: 288-298, 2015.*

Clemmensen, "Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice", EMBO Molecular Medicine, Feb. 4, 2015, 1-12.

Communication, "International Search Report and Written Opinion PCT/US16/27402", dated Nov. 29, 2016.

Deshmane, et al., "Monocyte Chemoattractant Protein-1 (MCP-1): An Overview", Journal of Interferon & Cytokine Research (vol. 29 N. 6), Dec. 5, 2008, 313-326.

Finan, "Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists", Molecular and Cellular Endocrinology (418), Jul. 4, 2015, 42-54.

(Continued)

*Primary Examiner* — Gyan Chandra

(74) *Attorney, Agent, or Firm* — Stephen A. Slusher

(57) **ABSTRACT**

The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.

**17 Claims, 7 Drawing Sheets**

**Specification includes a Sequence Listing.**